Woodward Diversified Capital LLC Sells 75,058 Shares of Genelux Co. (NASDAQ:GNLX)

Woodward Diversified Capital LLC decreased its stake in shares of Genelux Co. (NASDAQ:GNLX - Free Report) by 5.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,268,305 shares of the company's stock after selling 75,058 shares during the quarter. Genelux makes up 2.2% of Woodward Diversified Capital LLC's investment portfolio, making the stock its 8th biggest holding. Woodward Diversified Capital LLC owned approximately 3.67% of Genelux worth $2,993,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of GNLX. Brown Brothers Harriman & Co. increased its stake in Genelux by 76.2% in the third quarter. Brown Brothers Harriman & Co. now owns 21,075 shares of the company's stock valued at $50,000 after purchasing an additional 9,114 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of Genelux in the 2nd quarter valued at $56,000. XTX Topco Ltd acquired a new stake in Genelux during the 3rd quarter worth $59,000. Exchange Traded Concepts LLC lifted its position in Genelux by 89.0% in the third quarter. Exchange Traded Concepts LLC now owns 65,930 shares of the company's stock valued at $156,000 after acquiring an additional 31,047 shares during the last quarter. Finally, LifeSteps Financial Inc. grew its holdings in shares of Genelux by 17.6% during the third quarter. LifeSteps Financial Inc. now owns 78,255 shares of the company's stock worth $185,000 after purchasing an additional 11,719 shares during the last quarter. Institutional investors and hedge funds own 37.33% of the company's stock.

Genelux Price Performance

Shares of GNLX stock traded down $0.06 during trading hours on Wednesday, reaching $5.60. 656,387 shares of the company's stock were exchanged, compared to its average volume of 295,341. The company's 50 day moving average is $2.96 and its two-hundred day moving average is $2.64. The company has a market cap of $193.42 million, a P/E ratio of -5.89 and a beta of -1.46. Genelux Co. has a 1 year low of $1.60 and a 1 year high of $8.96.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on GNLX shares. HC Wainwright decreased their target price on Genelux from $32.00 to $30.00 and set a "buy" rating for the company in a research report on Friday, November 15th. Guggenheim started coverage on shares of Genelux in a report on Tuesday, October 29th. They issued a "buy" rating and a $8.00 target price on the stock. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $18.25.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.